Brief: Shanghai Henlius Biotech Says Application For Clinical Trial Of HLX43 For Injection Approved
27/01/2026 10:29
Jan 27 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: APPLICATION FOR CLINICAL TRIAL OF HLX43 FOR INJECTION WITH HLX07 & HANSIZHUANG APPROVED CLINICAL TRIAL APPROVED BY NMPA CHINA Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln